Endo International PLC (NASDAQ:ENDP) rose 2.9% during mid-day trading on Wednesday . The company traded as high as $24.93 and last traded at $24.34, with a volume of 4,627,595 shares trading hands. The stock had previously closed at $23.66.

A number of research analysts recently commented on the stock. Morgan Stanley reaffirmed a “hold” rating and set a $15.00 price objective (down from $50.00) on shares of Endo International PLC in a research report on Thursday, May 12th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $26.00 price objective on shares of Endo International PLC in a research report on Wednesday, May 18th. Leerink Swann downgraded shares of Endo International PLC from an “outperform” rating to a “market perform” rating and set a $23.00 price objective on the stock. in a research report on Friday, May 6th. Barclays PLC lowered their price objective on shares of Endo International PLC from $37.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, May 6th. Finally, Vetr downgraded shares of Endo International PLC from a “strong-buy” rating to a “buy” rating and set a $18.57 price objective on the stock. in a research report on Tuesday, August 2nd. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $39.95.

The firm’s market capitalization is $4.68 billion. The stock’s 50-day moving average price is $19.49 and its 200 day moving average price is $25.86.

Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings data on Monday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.12. The business earned $921 million during the quarter, compared to analyst estimates of $873.50 million. During the same quarter last year, the business earned $1.08 earnings per share. Endo International PLC’s revenue for the quarter was up 25.3% on a year-over-year basis. On average, equities analysts forecast that Endo International PLC will post $4.56 earnings per share for the current year.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.